Skip to content

8-KAccepted Nov 16, 7:17 AM ET

Larimar Therapeutics, Inc.: reports Q3 2026 results

LRMRLarimar Therapeutics, Inc.

Accepted (ET)

7:17 AM

Nov 16, 2026

Filed

Nov 16, 2026

Documents

12

Size

1.1 MB

Summary

Larimar Therapeutics, Inc.: reports Q3 2026 results

Updated

What happened

  • The filing says: On Nov 16, 2026, Larimar Therapeutics, Inc. announced its financial results and operational highlights for the third quarter ended Sep 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
  • The report is signed by Carole S. Ben-Maimon, M.D., Chief Executive Officer, dated Nov 16, 2026.

Key details

  • Item 2.02 reported results of operations and financial condition for the quarter ended Sep 30, 2026.
  • Exhibit 99.1 is the press release issued by Larimar Therapeutics, Inc. on Nov 16, 2026 and is furnished with the report.
  • Exhibit 104 is the cover page interactive data file embedded within the Inline XBRL document.
  • The Current Report on Form 8-K is dated Nov 16, 2026 and was signed by the CEO, Carole S. Ben-Maimon, M.D.

Why it may matter

  • Item 2.02 covers the company's results of operations and financial condition; Item 9.01 lists exhibits filed or furnished with the report, including the press release and the interactive XBRL cover page.
  • This filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing